Endo International PLC (ENDP) PT Set at $9.00 by Cantor Fitzgerald
Endo International PLC (NASDAQ:ENDP) has been assigned a $9.00 target price by investment analysts at Cantor Fitzgerald in a report released on Tuesday. The firm currently has a “hold” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential downside of 3.33% from the company’s previous close.
ENDP has been the subject of a number of other reports. William Blair reiterated a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Stifel Nicolaus downgraded Endo International PLC from a “buy” rating to a “hold” rating and reduced their target price for the stock from $22.00 to $15.00 in a research note on Friday, June 9th. Vetr upgraded Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 target price for the company in a research note on Wednesday, May 17th. Canaccord Genuity set a $14.00 target price on Endo International PLC and gave the stock a “hold” rating in a research note on Monday, May 22nd. Finally, BMO Capital Markets reissued a “hold” rating and set a $15.00 price target on shares of Endo International PLC in a report on Monday, May 1st. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $17.18.
Endo International PLC (ENDP) traded down 10.8582% during trading on Tuesday, reaching $8.2991. The company’s stock had a trading volume of 18,419,639 shares. The stock’s 50 day moving average is $11.45 and its 200-day moving average is $11.76. Endo International PLC has a 52 week low of $8.28 and a 52 week high of $24.93. The firm’s market cap is $1.85 billion.
Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.19. The business had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. Endo International PLC’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period last year, the company earned $0.86 earnings per share. On average, equities research analysts forecast that Endo International PLC will post $3.53 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/08/endo-international-plc-endp-pt-set-at-9-00-by-cantor-fitzgerald.html.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Macquarie Group Ltd. increased its position in Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the period. James Investment Research Inc. purchased a new position in Endo International PLC during the second quarter worth $113,000. Blair William & Co. IL purchased a new position in Endo International PLC during the second quarter worth $126,000. Point View Wealth Management Inc. increased its position in Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock worth $128,000 after buying an additional 1,254 shares during the period. Finally, Meeder Asset Management Inc. purchased a new position in Endo International PLC during the first quarter worth $139,000. 93.00% of the stock is currently owned by institutional investors.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.